The efficacy of targeted therapies in metastatic squamous cell carcinoma of the lung: a Turkish Oncology Group multicentre study

Basit Öğe Kaydı
dc.contributor.authorKilictas, Bilgesah
dc.contributor.authorAraz, Murat
dc.contributor.authorOruc, Ahmet
dc.contributor.authorCaglayan, Dilek
dc.contributor.authorEmin, Gamze
dc.contributor.authorYildirim, Atila
dc.contributor.authorAydin, Tayyip Ilker
dc.date.accessioned2026-04-04T13:33:33Z
dc.date.available2026-04-04T13:33:33Z
dc.date.issued2025
dc.departmentİnönü Üniversitesi
dc.description.abstractThis multicentre real-world study evaluated the efficacy of targeted therapies in Turkish patients with metastatic squamous cell lung carcinoma harbouring driver mutations. Sixty-four patients with alterations such as EGFR, ALK, and ROS1 who received targeted agents were retrospectively analysed. EGFR mutations were most common (67.2%). Among EGFR-TKI-treated patients, median progression-free survival (PFS) and overall survival (OS) were 12.4 and 14.3 months, respectively. Alectinib yielded a median PFS of 18.6 months and OS of 29.8 months in ALK-positive patients, while crizotinib produced a median PFS and OS of 7 months in ROS1-positive patients. The overall response rate was 50% and the disease control rate 84.4%. Although targeted therapies prolonged PFS compared with chemotherapy, this improvement did not translate into a significant OS advantage, likely influenced by retrospective design and treatment crossover. Findings represent real-world outcomes in a molecularly defined subgroup.
dc.identifier.doi10.1080/1120009X.2025.2601938
dc.identifier.issn1120-009X
dc.identifier.issn1973-9478
dc.identifier.orcid0000-0003-2843-2748
dc.identifier.orcid0000-0002-9316-7277
dc.identifier.orcid0000-0002-4632-9501
dc.identifier.orcid0000-0003-4629-6815
dc.identifier.orcid0000-0002-1549-7326
dc.identifier.orcid0000-0001-8014-4140
dc.identifier.orcid0009-0003-0923-5148
dc.identifier.pmid41414901
dc.identifier.scopus2-s2.0-105025555351
dc.identifier.scopusqualityQ3
dc.identifier.urihttps://doi.org/10.1080/1120009X.2025.2601938
dc.identifier.urihttps://hdl.handle.net/11616/109246
dc.identifier.wosWOS:001645100600001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTaylor & Francis Ltd
dc.relation.ispartofJournal of Chemotherapy
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250329
dc.subjectSquamous cell lung cancer
dc.subjecttargeted therapy: EGFR mutation
dc.subjectALK rearrangement
dc.subjectreal-world data
dc.subjectprogression-free survival
dc.subjectoverall survival
dc.subjectreal-world evidence
dc.titleThe efficacy of targeted therapies in metastatic squamous cell carcinoma of the lung: a Turkish Oncology Group multicentre study
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu